Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Deals Of The Week: Tire-Kicking Season Continues Full-Swing

Executive Summary

As Roche’s reported interest in buying rare-disease specialist Alexion faded, new suitors popped up for oncology specialist Onyx. Plus news on deals between Spectrum and Talon, Pfizer and Sequella, Medtronic and Amgen, and a new direction for Rexahn.

You may also be interested in...



Rexahn Adds Drug Conjugate Platform To Its Oncology Offerings

The Rockville, Md.-based biotech hopes to bring more value to shareholders through a slew of polymer-conjugated cancer drugs that it will add to its pipeline while it continues moving its three lead cancer compounds forward.

Spectrum Bets On Marqibo In NHL With Low-Priced Talon Acquisition

Spectrum gains an approved drug with the deal and aims for label expansion. Talon’s high-profile investors are counting on an increase in Spectrum share price and post-acquisition milestones to break even.

Deals Of The Week Wonders: Who Will Buy Onyx?

Oncology-focused pharmas and multiple myeloma players, as well as would-be MM competitors, top Wall Street’s list of possible Onyx buyers. A successful deal could aid the longstanding biotech rally that has retrenched in recent weeks.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

PS055491

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel